Contribute Try STAT+ Today

policy

Most Read

bacteria SOS antimicrobial resistance

First Opinion By Sevahn Vorperian and Stephen Quake

The PASTEUR Act can help win the war against superbugs

insulin biosimilar

Biotech By Damian Garde and Nicholas Florko

Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug

Hydrocodone

Health By Dylan Scott

FDA to require strong warnings about combining pain pills with anxiety medication

Las Vegas vaccine

First Opinion By Dorit R. Reiss, I. Glenn Cohen and Carmel Shachar

‘Authorization’ status is a red herring when it comes to mandating Covid-19 vaccination

2019 PET scan

Politics By Rachel Cohrs

Biogen isn’t the only drug company that will profit from the new Alzheimer’s drug Aduhelm

A STAT Investigation By Charles Piller

Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients

Fertilized Human Egg

Health By Andrew Joseph

‘They don’t want his story to end’: Efforts to save the sperm of the deceased come with heartache and tough questions

3/1 Trump

Exclusive By Rachel Cohrs

The Trump administration quietly spent billions in hospital funds on Operation Warp Speed

All Coverage

Eric Lander pointing

Health By Lev Facher

For the first time ever, Lander’s White House science office will have an entire wing dedicated to health

Ron Wyden (D-OR)

Politics By Rachel Cohrs

Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal

advertisement

D.C. Insight IMAGE

D.C. Diagnosis By Nicholas Florko

Are pharma mergers bad for biotech?

Politics By Rachel Cohrs

Washington’s antitrust push could limit Amazon, Google’s health care ambitions

Ron Wyden (D-OR)

Politics By Nicholas Florko

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

D.C. Insight IMAGE

D.C. Diagnosis By Rachel Cohrs

The lonely quest to create a commission to investigate Covid-19

Dr. Michelle McMurry-Heath Q&A

Politics By Nicholas Florko

BIO’s chief on the FDA commissioner rumors, drug pricing, and IP rights

Stack of documents

Politics By Rachel Cohrs

Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates

insulin biosimilar

Business By Andrew Joseph

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

research funding

First Opinion By David Blumenthal

Restore a better balance to public-private funding of biomedical research

red & blue DNA strand

Politics By Megan Molteni

California could become first state to mandate biosecurity screening by mail-order DNA companies

blue syringes

First Opinion By Parsa Erfani, Lawrence O. Gostin and Vanessa Kerry

Beyond a symbolic gesture: What’s needed to turn the IP waiver into Covid-19 vaccines

Moderna Vaccine shipment

First Opinion By Jonathan Doh

Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access

expanding claims databases

Opinions+ By John Freedman

The many benefits of expanding the reach of state all-payer claims databases

Eric Schmidt

Health Tech By Andrew Joseph

Former Google CEO Schmidt says AI ‘will have its biggest impact’ in health care

HHS Xavier Becerra

Hospitals By Rachel Cohrs

HHS plans to open up billions in hospital Covid-19 grants in coming weeks

Sen. Ron Wyden

Politics By Rachel Cohrs

Top Senate Democrat heads back to drawing board on drug pricing

masked Fauci

Politics By Lev Facher

Do public health officials need to be political activists? A fight over an HIV crisis renews the question

Door Knocking

Health By Alicia Diaz

Door knocking works to get information to immigrant communities. Why aren’t more places using it for Covid-19?

Mr. Peter Welch

Politics By Nicholas Florko and Rachel Cohrs

Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support

Illumina Grail vertical merger

First Opinion By Joe Lonsdale

FTC’s challenge to Illumina’s vertical merger with Grail is all wrong

1/21 executive order

Exclusive By Nicholas Florko

Biden officials met privately with 3M, AmerisourceBergen, PhRMA, and more to debate shoring up the national stockpile

remote inspection

Opinions+ By Patrick McLaughlin and Tyler Richards

The FDA should embrace remote and automated drug inspection technology

Tom Nickels

Politics By Rachel Cohrs

The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry

Wyden & Crapo

Politics By Nicholas Florko

Hints emerge about a key Senate committee’s plans for health care